Point of Care Respiratory
Acceava H. pylori BioStar OIA CdTOX A BioStar OIA SHIGATOX Clearview C.diff A Clearview H. pylori Clearview ULTRA FOB TOX A/B QUIK CHEK
Acceava®, BioStar®, Clearview®, and OIA® are registered trademarks of the Inverness Medical family of companies. TOX A/B QUIK CHEK® is a registered trademark of TechLab, Inc.
Clearview ULTRA FOB

TOX A/B QUIK CHEK® has a larger sample well to make testing for C. difficile toxins A and B fast, easy, accurate, and clean.

Easy to Use

  • A larger sample well means neater, quicker placement.
  • Novel patent-pending technology smoothly disperses sample within the device.
  • The chance of clogging is minimized, greatly reducing unwanted spillovers.

 

Easy to Read

  • Two lines mean C. difficile toxin A/B is present
  • Internal control line validates the QC result in the same reaction window

 

Highly Accurate

  • >90% sensitivity*
  • >99% specificity*

 

TOX A/B QUIK CHEK Testing Procedure

Download sample Procedure Card

 

About C. difficile

Clostridium difficile is a gram-positive, spore-forming anaerobic bacterium. C. difficile is the leading cause of diarrhea outbreaks or C. difficile-associated disease (CDAD) in hospitals, infirmaries, and elderly care units. CDAD is usually caused by antibiotic or chemotherapy disturbing the normal balance of the gut flora.1 Virtually any antibiotic is capable of causing the condition and studies have shown reduced antibiotic prescription levels can significantly reduce CDAD cases.2 Outbreaks in nosocomial environments are difficult to control since the bacteria produces spores that are difficult to eradicate.2

C. difficile has been identified as the organism responsible for toxin production.3 C. difficile produces two large molecular weight toxins, designated A and B. Toxin A is considered to play a more important role in the etiology of CDAD.4 The toxins produce symptoms in CDAD patients, which can range from mild diarrhea to pseudomembranous colitis (PMC). PMC manifests as adherent yellowish-white plaques on the intestinal mucosa. Rapid diagnosis of C. difficile is therefore important in order to treat patients and prevent spread of the disease.2

References

  1. Hamm L. Clostridium difficile. Pediatr Pharm. 2000;6(6).
  2. McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997; 40:707-711.

 

Specifications

Order No. 30394

Qty: 25 Tests

CPT*: 87803, 87324

CLIA: Non-waived

Contact: (800) 637-3717

Clearview ULTRA FOB Launch Product Demonstration Useful Downloads Product Brochure Package Insert Procedure Card CLSI Procedure MSDS
* It is always the provider's responsibility to establish appropriate coding & charges.